Figure 3

The value of ¹⁸ FDG PET/CT value in determining the management of a patient with craniofacial bone sarcoma. The initial response to treatment, after four cycles of MAP chemotherapy, is documented by both MRI (A versus B) and ¹⁸FDG PET/CT (D versus E). At the subsequent restaging, performed early due to worsening pain, the MRI scan (C) continued to demonstrate stable disease while the ¹⁸FDG PET/CT demonstrated overt disease progression with an increase in SUV from 21 to 42 (F).